StockNews.com Initiates Coverage on Fresenius Medical Care (NYSE:FMS)

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report report published on Thursday morning. The brokerage issued a strong-buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Truist Financial boosted their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company.

Fresenius Medical Care Price Performance

FMS opened at $22.48 on Thursday. The company has a 50-day moving average of $20.93 and a 200-day moving average of $20.32. The company has a market capitalization of $13.19 billion, a P/E ratio of 18.58, a PEG ratio of 1.03 and a beta of 0.91. Fresenius Medical Care has a 1-year low of $17.93 and a 1-year high of $22.76. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wulff Hansen & CO. boosted its stake in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the period. Moran Wealth Management LLC boosted its stake in Fresenius Medical Care by 47.0% during the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP boosted its stake in Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after purchasing an additional 48,554 shares during the period. Triasima Portfolio Management inc. boosted its stake in Fresenius Medical Care by 27.4% during the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock valued at $1,631,000 after purchasing an additional 18,360 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Fresenius Medical Care by 3.3% during the 3rd quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after purchasing an additional 2,386 shares during the period. 8.25% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.